|Dr. Laura K. Shawver||CEO, Pres & Director||606.48k||N/A||1958|
|Dr. Floyd E. Romesberg||Scientific Founder & Director||2.68k||N/A||1966|
|Dr. Marcos Milla Ph.D.||Chief Scientific Officer||457.71k||N/A||1963|
|Dr. Joseph Leveque||Chief Medical Officer||448.76k||N/A||1961|
|Terry L. Button||VP & Director||N/A||N/A||N/A|
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
Synthorx, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.